Difference between revisions of "Gilteritinib (Xospata)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 7: Line 7:
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
 
*11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] with a [[Biomarkers#FLT3|FLT3]] [[Biomarkers#Alterations|mutation]] as detected by an FDA-approved test. ''(Based on ADMIRAL)''
 
*11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory [[Acute_myeloid_leukemia|acute myeloid leukemia (AML)]] with a [[Biomarkers#FLT3|FLT3]] [[Biomarkers#Alterations|mutation]] as detected by an FDA-approved test. ''(Based on ADMIRAL)''
 
+
==History of changes in EMA indication==
 +
*10/24/2019: Initial authorization
 
== Patient Drug Information==
 
== Patient Drug Information==
 
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf Gilteritinib (Xospata) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf Gilteritinib (Xospata) Package Insert]</ref>
 
*[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf Gilteritinib (Xospata) Package Insert]<ref>[https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211349s001lbl.pdf Gilteritinib (Xospata) Package Insert]</ref>
Line 28: Line 29:
  
 
[[Category:FDA approved in 2018]]
 
[[Category:FDA approved in 2018]]
 +
[[Category:EMA approved in 2019]]

Revision as of 20:50, 1 January 2023

Mechanism of action

Tyrosine kinase inhibitor of FLT3, AXL, and ALK

Diseases for which it is used

History of changes in FDA indication

  • 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Based on ADMIRAL)

History of changes in EMA indication

  • 10/24/2019: Initial authorization

Patient Drug Information

Also known as

  • Code name: ASP2215
  • Brand name: Xospata

References